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Summary
Mastocytosis is a rare disease with reported high interleukin-6 (IL6) levels influenc-
ing disease severity. The present study investigated polymorphisms within the genes
that encode IL6 and its receptor (IL6R) in relation to mastocytosis development in
a case-control design. Analysis of the IL6R Asp358Ala polymorphism showed that
carriers of the AA genotype had a 25-fold lower risk for mastocytosis than those
with the AC or CC genotypes. No association with mastocytosis was found for the
IL6174G/C polymorphism, however, it may influence the effect of IL6R polymor-
phism. To the best of our knowledge this is the first study analysing IL6/IL6R poly-
morphisms in mastocytosis.
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Mastocytosis is a rare disease defined by autonomous prolifera-
tion and activation of mast cells resulting from activating muta-
tions in KIT, which encodes the receptor for stem cell factor
(Orfao et al, 2007). Mastocytosis diagnosis and classification
has been well defined and the disease has been recently included
in the World Health Organization (WHO) group of myelopro-
liferative neoplasms (MPNs) (Horny et al, 2008; Valent et al,
2007). Clinical manifestations of the systemic form (SM) are
caused by tissue infiltration of proliferating mastocytes into
different organs and the release of their mediators while the
cutaneous form (CM) is a localized type of the disease. The
presence of activating KIT mutations alone is not sufficient to
account for the different clinical forms of mastocytosis, suggest-
ing that other mutations or polymorphisms in genes important
in regulation of mast cell turnover are likely to influence the
clinical outcome of the disease. One such candidate genemight be
IL6, which encodes the multifunctional cytokine, interleukin-6
(IL6). Recent data indicate that mastocytosis patients may
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exhibit elevated plasma IL6 levels, which are in close correlation
to disease severity (Brockow et al, 2005).
Beside various clinical factors (age, gender, inflamma-
tion, etc.), IL6 level may be influenced by different genetic
variations. A G to C substitution at position 174 of the
IL6 gene promoter was shown to decrease IL6 transcription
in vitro and, in accordance, differences in IL6 serum levels
between carriers of the wildtype and variant alleles of the
polymorphism were reported (Fishman et al, 1998; Rivera-
Chavez et al, 2003), however others failed to reproduce
these findings (Qi et al, 2006). A functional polymorphism
(Asp358Ala) in exon 9 of the IL6R gene, resulting in the
substitution of one of the two amino acids at the site of
proteolytic cleavage, leads to altered shedding of mem-
brane-bound IL6 receptor (IL6R) (Galicia et al, 2004).
Given that soluble IL6R (sIL6R) binds to IL6, circulating
IL6 levels may be influenced by circulating receptor levels
via sequestration (Rose-John et al, 2006). Accordingly,
many studies also found a minor allele (C) of this poly-
morphism was associated with higher levels of sIL6R and
IL6 (Galicia et al, 2004; Reich et al, 2007).
The aim of the present case-control study was to compare
the frequency of IL6 174 G/C and IL6R Asp358Ala poly-
morphisms between mastocytosis patients and healthy
controls to evaluate their role in heritable mastocytosis risk.
Materials and methods
DNA samples and data were collected from 66 patients; 19
from Vienna, 24 from Gdansk and 23 from Budapest [male/
female ratio: 26/40; mean age: 429 years (range 18–80)].
Patients were diagnosed according to the WHO criteria: 27
had CM, 27 had indolent systemic mastocytosis (ISM), three
had smoldering systemic mastocytosis (SSM), six had SM in
association with a haematological disease other than masto-
cytosis (SM-AHNMD), two had the aggressive systemic
(ASM) form of the disease and one presented with mast cell
leukaemia (MCL).
The control group consisted of 99 subjects. Exclusion crite-
ria for controls were malignancies and immunopathological
disorders. Mean age was 68 years (range 37–91) with a 45/54
male/female sex ratio. All patients and controls gave informed
consent and the study was approved by the national scientific
ethical committee (ETT TUKEB 12236-45/2004-1018EKU).
Ethylenediaminetetraacetic acid (EDTA)-anticoagulated
blood samples were collected from each patient and control,
and genomic DNA was extracted from white blood cells by the
salting-out procedure. The 174G/C polymorphism of the IL6
gene (rs1800795) was analysed with polymerase chain reac-
tion-restriction fragment length polymorphism (PCR-RFLP)
and the Asp358Ala single nucleotide polymorphism (SNP) of
the IL6R gene (A>C, rs2228145, previously: rs8192284) was
genotyped using a TaqMan SNP Genotyping Assay (Life Tech-
nologies, Carlsbad, CA, USA) as described previously (Aladzsi-
ty et al, 2009).
Deviation from Hardy–Weinberg equilibrium was evaluated
and association analysis was performed by chi-square test
using the GRAPHPAD PRISM v.4.0 and Statistical Package for the
Social Sciences (SPSS) v.13.0 software. All tests were two-tailed
and P < 005 was considered to be statistically significant.
Results
There was no significant difference between mastocytosis
patients and controls in the frequency of 174G/C polymor-
phism of the IL6 gene (Table I).
For the Asp358Ala SNP of the IL6R gene, the AA genotype and
A allele was found to be less frequent in mastocytosis patients when
compared to controls (P = 00317 and P = 00229, respectively)
(Table I). The odds ratio (OR) for developing mastocytosis of AA
genotype carriers was 04019 [95% confidence interval
(CI) = 02013–08021; P = 00088], whereas C allele carriers
(AC + CC) had a higher risk (OR = 2488; 95%CI = 1247–
4967; P = 00088) for the disease.
Analysis of the combined effect of the two studied poly-
morphisms showed that the AA genotype of IL6R polymor-
phism, together with the G allele of IL6 polymorphism, were
less frequent in mastocytosis patients than in controls
(P = 000026) with an OR of 02348 (95%CI = 01043–
05289; P = 00003) (Fig 1).
Discussion
The aim of the present study was to evaluate the role of two
polymorphisms influencing circulating IL6 level in heritable
mastocytosis risk by comparing mastocytosis patients and
controls. Analysis of the IL6R Asp358Ala polymorphism
showed that frequencies of the A allele and the AA genotype
were significantly lower in mastocytosis patients in compari-
son to healthy controls. Carriers of the AA genotype had an
approximately 25-fold lower risk for mastocytosis than those
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Fig 1. Combined distribution of IL6 and IL6R polymorphisms in
mastocytosis patients and controls. Upper line on the x-axis shows
genotypes of IL6 174G /C polymorphism. The lower line shows
genotypes of IL6R Asp358Ala (A/C) single nucleotide polymorphism.
Differences between carriers of both IL6R AA and IL6 GG/GC versus
all other genotypes were evaluated by chi-square test.
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with the AC or CC genotypes (OR = 04019). The
IL6174G/C polymorphism showed no association with
mastocytosis but a protective effect of IL6R AA genotype was
found to be elevated in the presence of the G allele of the
IL6174G/C polymorphism. The risk for developing masto-
cytosis was more than 4-fold lower (OR = 02348) in carriers
of both IL6R AA and IL6 GG/GC genotypes than the rest of
the patients.
Interleukin-6 is a proinflammatory cytokine involved in
host defence mechanisms. Binding of IL6 to IL6 receptor
activates mast cell signalling through the Janus kinase (JAK)
and Btk pathways, which play an important role in the path-
ogenesis of mastocytosis. It has been reported that patients
with myeloproliferative neoplasms have elevated levels of IL6,
regarding JAK1 hyperactivation, therefore might benefit from
JAK1/2 inhibitor therapy (Panteli et al, 2005; Tefferi, 2000;
Cardama et al, 2010;.). Wickenhauser et al, (1999) noted
aberrant IL6/IL6R serum levels in polycythaemia vera – a
representative MPN – of yet unknown significance while
Brockow et al, (2005) have reported elevated levels of IL6 in
mastocytosis. Studies on IL6R and IL6 polymorphisms in
MPNs – to our present knowledge – have not yet been
reported.
Interleukin-6 level may be influenced by different genetic
variations, two of which were selected for analysis in this study.
The AA genotype of the IL6R Asp358Ala polymorphism, found
to be a protective factor against mastocytosis development in
this study, was previously reported to be associated with lower
circulating sIL6R and IL6 levels. Hence, it is rational to
hypothesize, that genotypes of this polymorphism influence
mastocytosis development through decreasing IL6 levels,
resulting in lower activation of mast cells. In addition, changes
in sIL6R level may also have an important role as sIL6R is
capable of sensitizing target cells toward IL6 and eliciting a
biological response in cells that do not express membrane-
bound IL6R but only the signal transducing gp130 subunit
(Brockow et al, 2005; Rose-John et al, 2006). A direct role of
the IL6 174G/C SNP in mastocytosis development was not
found; however, it may have an influence on the effect of the
IL6R Asp358Ala polymorphism.
This preliminary study has shown that the AA genotype
of the IL6R Asp358Ala polymorphism may confer protec-
tion against mastocytosis disease development; however,
large cohort studies are needed to confirm this finding.
Therefore we are planning to analyse IL6 serum levels in
parallel with IL6 and IL6R gene polymorphisms in differ-
ent mastocytosis subtypes in a larger patient cohort in a
more extended international collaboration. Given that there
are several KIT mutations in mastocytosis (Orfao et al,
2007), most of which have unknown consequences, future
investigations should study their possible relationship with
IL6 and IL6R genetic polymorphisms as well.
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